Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819446 | 0.83 | NPC1 (0.44) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL17816408 | 0.83 | NPC1 (0.41) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9816728 | 0.82 | NPC1 (0.47) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23352536 | 0.81 | NPC1 (0.50) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13545147 | 0.76 | PTGS1 (0.44) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL536549 | 0.76 | NPC1 (0.48) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| Formic Acid SCHEMBL28186935 | 0.76 | NPC1 (0.46) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13725781 | 0.75 | NPC1 (0.47) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9158941 | 0.75 | NPC1 (0.47) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4324112 | 0.75 | NPC1 (0.47) | NPC1RAB9AALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268402-B2 | Fullerene film and fullerene polymer both produced from fullerene derivative and processes for producing these | FRONTIER CARBON CORPORATION (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20100317767-A1 | FULLERENE FILM AND FULLERENE POLYMER BOTH PRODUCED FROM FULLERENE DERIVATIVE AND PROCESSES FOR PRODUCING THESE | FRONTIER CARBON CORPORATION (JP) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317767-A1 | FULLERENE FILM AND FULLERENE POLYMER BOTH PRODUCED FROM FULLERENE DERIVATIVE AND PROCESSES FOR PRODUCING THESE | RNF168, FTO, MGMT | NPC1 1117/4885RAB9A 800/4885ALDH1A1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.